Laura Chico
Stock Analyst at Wedbush
(3.63)
# 828
Out of 5,024 analysts
224
Total ratings
44.81%
Success rate
8.11%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $15 → $11 | $4.12 | +166.99% | 3 | Sep 30, 2025 | |
| PEPG PepGen | Maintains: Outperform | $9 → $8 | $4.67 | +71.31% | 12 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $42 → $44 | $35.48 | +24.01% | 9 | Sep 12, 2025 | |
| TRML Tourmaline Bio | Downgrades: Neutral | $48 | $47.91 | +0.19% | 3 | Sep 9, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $9.38 | +91.98% | 3 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $14 | $6.19 | +126.17% | 3 | Aug 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $36.12 | -39.09% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $41.10 | +4.62% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $26.35 | +21.44% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $2.40 | +108.33% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $5.04 | +177.78% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $138.32 | +1.94% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $32.52 | +4.55% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $28.67 | -40.70% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $6.66 | +170.47% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $122.58 | +6.05% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $143.52 | -15.69% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $21.87 | +23.46% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $5.64 | -29.10% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $16.08 | +86.57% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $30.80 | -15.58% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $54.75 | -48.86% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $15.02 | +186.28% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.70 | +76.47% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $11.88 | +135.69% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $24.83 | +16.79% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $5.21 | +34.36% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $21.73 | +93.28% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.56 | +1,864.29% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $7.01 | -28.67% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $53.00 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $5.28 | -5.30% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $17.35 | +755.91% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $16.71 | +4,210.09% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $108.01 | +159.24% | 1 | Apr 21, 2017 |
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $4.12
Upside: +166.99%
PepGen
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.67
Upside: +71.31%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $35.48
Upside: +24.01%
Tourmaline Bio
Sep 9, 2025
Downgrades: Neutral
Price Target: $48
Current: $47.91
Upside: +0.19%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $9.38
Upside: +91.98%
Solid Biosciences
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $6.19
Upside: +126.17%
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $36.12
Upside: -39.09%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $41.10
Upside: +4.62%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $26.35
Upside: +21.44%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.40
Upside: +108.33%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.04
Upside: +177.78%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $138.32
Upside: +1.94%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $32.52
Upside: +4.55%
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $28.67
Upside: -40.70%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $6.66
Upside: +170.47%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $122.58
Upside: +6.05%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $143.52
Upside: -15.69%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $21.87
Upside: +23.46%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $5.64
Upside: -29.10%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $16.08
Upside: +86.57%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $30.80
Upside: -15.58%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $54.75
Upside: -48.86%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $15.02
Upside: +186.28%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.70
Upside: +76.47%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $11.88
Upside: +135.69%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.83
Upside: +16.79%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $5.21
Upside: +34.36%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $21.73
Upside: +93.28%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.56
Upside: +1,864.29%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $7.01
Upside: -28.67%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $53.00
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $5.28
Upside: -5.30%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $17.35
Upside: +755.91%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $16.71
Upside: +4,210.09%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $108.01
Upside: +159.24%